{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:54:24Z","timestamp":1794563664667,"version":"4.9.1"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.diabres.2024.111806","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:31:35Z","timestamp":1722886295000},"page":"111806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis"],"prefix":"10.1016","volume":"215","author":[{"given":"Laura D","family":"Lomeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimitha M","family":"Kodali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi E","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M","family":"Pantalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.diabres.2024.111806_b0005","doi-asserted-by":"crossref","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"7","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.diabres.2024.111806_b0010","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.diabres.2024.111806_b0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.21037\/atm.2018.02.24","article-title":"Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions","volume":"6","author":"Scusho","year":"2018","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.diabres.2024.111806_b0020","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4158\/EP11290.OR","article-title":"Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-Peptidase-4 inhibitors in the outpatient setting","volume":"18","author":"Lando","year":"2012","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.diabres.2024.111806_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.diabres.2024.111806_b0030","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/00042737-200012120-00015","article-title":"Gallstones in obesity and weight loss","volume":"12","author":"Erlinger","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.diabres.2024.111806_b0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"10.1016\/j.diabres.2024.111806_b0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/jgh3.12060","article-title":"Differences between the outcome of recurrent acute pancreatitis and acute pancreatitis","volume":"2","author":"Mallick","year":"2018","journal-title":"JGH Open"},{"issue":"3","key":"10.1016\/j.diabres.2024.111806_b0045","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0018578719882323","article-title":"Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength","volume":"56","author":"Neha","year":"2021","journal-title":"Hosp Pharm."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724007162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724007162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T05:30:09Z","timestamp":1724477409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822724007162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":9,"alternative-id":["S0168822724007162"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111806","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111806"}}